Second Ebola Vaccine Trial Underway In Sierra Leone
Agence France-Presse: Ebola vaccine trial begins in Sierra Leone
“Thousands of health care workers in areas of Sierra Leone that are grappling with Ebola will now begin receiving an experimental vaccine against the often deadly virus, officials said Tuesday…” (4/14).
The Hill: CDC begins Ebola vaccine trial in Sierra Leone
“…The Centers for Disease Control and Prevention (CDC) has partnered with local health officials and disease researchers in Sierra Leone to launch the trial, which will include 6,000 health care workers on the frontlines of the disease…” (Ferris, 4/14).
ScienceInsider: Second Ebola vaccine trial may be too little, too late
“…Since peaking at the end of November, the number of newly reported cases in Sierra Leone has dropped steadily, from 95 four weeks ago to just 21 last week. That makes it very unlikely, that the trial — led by the U.S. Centers for Disease Control and Prevention (CDC) and the Sierra Leone Ministry of Health and Sanitation — can get a statistically significant result, says Stephan Becker, a virologist at the University of Marburg, Germany…” (Kupferschmidt, 4/14).
USA TODAY: Testing of Ebola vaccine is underway in Sierra Leone
“…The vaccine being rolled out in Sierra Leone was developed by the Public Health Agency of Canada and licensed to NewLink Genetics, which has licensed the vaccine to Merck. The vaccine has been tested on 800 people in Africa, Canada, Europe, and the USA. A second Ebola vaccine, developed at the National Institutes of Health and GlaxoSmithKline, is also in clinical trials in West Africa…” (Szabo, 4/14).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.